We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

133 hedge funds and large institutions have $1.68B invested in Neurocrine Biosciences in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 44 increasing their positions, 46 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

14% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 22

0% more funds holding

Funds holding: 133 → 133 (0)

4% less repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 46

11% less capital invested

Capital invested by funds: $1.88B → $1.68B (-$199M)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

67% less call options, than puts

Call options by funds: $17.4M | Put options by funds: $52.4M

Holders
133
Holders Change
–
Holders Change %
0%
% of All Funds
3.55%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
25
Increased
44
Reduced
46
Closed
22
Calls
$17.4M
Puts
$52.4M
Net Calls
-$35.1M
Net Calls Change
-$37.4M

Top Buyers

Rank Fund Capital Flow
1
Jennison Associates
Jennison Associates
New York
+$16.7M
2
Millennium Management
Millennium Management
New York
+$16.7M
3
PC
PointState Capital
New York
+$14.2M
4
VAM
Visium Asset Management
New York
+$12.8M
5
CCI
Columbus Circle Investors
+$10.3M

Top Sellers

Rank Fund Capital Flow
1
ACM
Americafirst Capital Management
California
-$734M
2
GPP
Great Point Partners
Connecticut
-$22M
3
PA
Perceptive Advisors
New York
-$18.9M
4
Loomis, Sayles & Company
Loomis, Sayles & Company
Massachusetts
-$10.6M
5
TCM
Tekla Capital Management
Massachusetts
-$5.34M
Name Holding Trade Value Shares
Change 		Change in
Stake
CS
51
Candriam SCA
Luxembourg
$4.69M +$3.98M +210,000 New
GC
52
Guggenheim Capital
Illinois
$4.52M +$152K +8,032 +4%
Barclays
53
Barclays
United Kingdom
$3.63M +$241K +12,717 +8%
Invesco
54
Invesco
Georgia
$3.38M +$2.85M +150,480 +21,809%
California State Teachers Retirement System (CalSTRS)
55
California State Teachers Retirement System (CalSTRS)
California
$3.16M +$22.7K +1,199 +0.9%
QI
56
QS Investors
New York
$2.82M +$2.39M +126,352 New
AllianceBernstein
57
AllianceBernstein
Tennessee
$2.81M – – –
JP Morgan Chase
58
JP Morgan Chase
New York
$2.53M +$2.15M +113,265 New
EAM
59
Eventide Asset Management
Massachusetts
$2.51M +$296K +15,600 +16%
TA
60
Teachers Advisors
New York
$2.32M – – –
GH
61
GAM Holding
Switzerland
$2.23M +$1.19M +63,000 +170%
Morgan Stanley
62
Morgan Stanley
New York
$2.2M +$916K +48,368 +96%
AIG
63
American International Group
New York
$2.01M -$241K -12,719 -12%
Prudential Financial
64
Prudential Financial
New Jersey
$1.96M -$17.1K -900 -1%
Swiss National Bank
65
Swiss National Bank
Switzerland
$1.88M +$37.9K +2,000 +2%
Wells Fargo
66
Wells Fargo
California
$1.82M -$321K -16,963 -17%
BlackRock
67
BlackRock
New York
$1.65M -$724K -38,200 -34%
State Board of Administration of Florida Retirement System
68
State Board of Administration of Florida Retirement System
Florida
$1.57M -$417 -22 -0%
RhumbLine Advisers
69
RhumbLine Advisers
Massachusetts
$1.53M -$70.3K -3,710 -5%
PAM
70
Paradigm Asset Management
New York
$1.5M -$153K -8,100 -11%
ProShare Advisors
71
ProShare Advisors
Maryland
$1.49M -$49.8K -2,629 -4%
VFA
72
Virtus Fund Advisers
Connecticut
$1.45M +$5.95K +314 +0.5%
Royal Bank of Canada
73
Royal Bank of Canada
Ontario, Canada
$1.43M +$1.09M +57,695 +946%
AQR Capital Management
74
AQR Capital Management
Connecticut
$1.41M -$159K -8,400 -12%
DBG
75
De Burlo Group
Massachusetts
$1.37M -$3.79K -200 -0.3%
1 2
3
4 5

NBIX Hedge Fund Activity: Q4 2014 in Review

133 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q4 2014, worth a combined $1.68B — down 11% from $1.88B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new NBIX positions and 22 closed out — a net gain of 3 holders — while 44 added to existing stakes and 46 trimmed.

The largest buyer was Jennison Associates, opening a new position worth an estimated $16.7M. The largest seller was Americafirst Capital Management, exiting entirely with an estimated $734M sold.

  • 133 institutional investors held Neurocrine Biosciences (NBIX) as of Q4 2014, unchanged from Q3 2014.
  • Funds reported $1.68B of Neurocrine Biosciences stock for Q4 2014, down 11% quarter-over-quarter.
  • 25 funds opened new Neurocrine Biosciences positions in Q4 2014 and 22 closed out, a net change of +3 holders.
  • The largest Neurocrine Biosciences buyer in Q4 2014 was Jennison Associates, an estimated $16.7M added.
  • The largest Neurocrine Biosciences seller in Q4 2014 was Americafirst Capital Management, an estimated $734M sold.

Based on aggregated 13F filings for Q4 2014.